Live

China, EU retaliate as Trump's massive tariffs kick in across the world. See the latest.

OTC Markets OTCPK - Delayed Quote USD

Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)

9.51

0.00

(0.00%)

As of April 8 at 4:00:00 PM EDT. Market Open.

SNBL and Tasso, Inc. to Establish Joint Venture in Japan

TOKYO & KAGOSHIMA, Japan & SEATTLE, March 27, 2025--SNBL and Tasso form Japan JV to distribute Tasso’s self-blood collection device, advancing telemedicine and patient-centric care in Japan.

Business Wire 12 days ago

SBLOF
0.00%
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced the resubmission of the new drug application (NDA) for the investigational product STS101 (dihydroergotamine nasal powder) for the acute treatment of migraine with or without aura.

PR Newswire 5 months ago

SBLOF
0.00%
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced publication the STS101 ASCEND Phase 3 long-term, open-label safety trial in CNS Drugs. STS101 is the only produ

PR Newswire 5 months ago

SBLOF
0.00%
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were

PR Newswire 9 months ago

SBLOF
0.00%

Performance Overview

Return	SBLOF	Nikkei 225 (^N225)
YTD	-126.01%	-20.51%
1-Year	+45.67%	-20.26%
3-Year	-43.96%	+17.52%